



Prothena Corporation plc
Investor Relations Department
331 Oyster Point Blvd
South San Francisco, CA 94080
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: PRTA

Last Trade:	57.91
Trade Time:	4:00 PM ET Oct 20, 2017
Change:	-0.62 (-1.059%)
Day Range	57.77 - 59.12
52-Week Range	40.58 - 70.00
Volume	171,437

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. Our antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and ATTR amyloidosis (PRX004).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Sep 28, 2017

[Prothena Reports Results from Phase 1b Multiple Ascending Dose Study of PRX003 in Patients with Psoriasis](#)

Sep 18, 2017

[Prothena Presents New Research Supporting Clinical Relevance of Å Cardiac Biomarker NT-proBNP in AL Amyloidosis](#)

Aug 15, 2017

[Prothena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual Meeting](#)

Aug 8, 2017

[Prothena Reports Second Quarter 2017 Financial Results and Provides R&D Update](#)

Aug 1, 2017

[Prothena to Report Second Quarter 2017 Financial Results on August 8](#)

Financials [\[View all \]](#)

[Second Quarter Financial Results](#)

Feb 27, 2017

[Annual Report \(10-K\)](#)

Mar 31, 2017

[Proxy Statement \(DEF 14A\)](#)

Aug 9, 2017

[Quarterly Report \(10-Q\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)

Nov 2, 2016

[Quarterly Report \(10-Q\)](#)